Filed Pursuant to Rule 433Issuer Free Writing Prospectus dated May 6, 2024Relating to Preliminary Prospectus dated May 6, 2024Registration No. 333-278866 LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has signed a non-binding letter of intent (“LOI”) to enter into a strategic partnership with ECO Laboratory, a Massachusetts-based clinical laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).

根据2024年5月6日第433条规则提交的发行人免费书面招股说明书与2024年5月6日的初步招股说明书有关，注册号为333-278866，马萨诸塞州列克星敦市，2024年5月7日（环球通讯社）——T2生物系统公司（纳斯达克：TTOO），一家快速检测败血症病原体和抗生素耐药基因的领先公司，今天宣布已签署一份不具约束力的意向书（“LOI”），与ECO Laboratory建立战略伙伴关系，ECO Laboratory是一家经临床实验室改进修正案（CLIA）认证的位于马萨诸塞州的临床实验室。

ECO Laboratory was founded by Karen Weeks, who has been at the forefront of Lyme disease research and testing for decades. She is co-author of extensive publications pertaining to tick-borne diseases, including The New England Journal of Medicine and The Journal of Infectious Diseases. While supervising the Virology Department at the Massachusetts Department of Public Health, and working directly with Allen Steere, MD at Tufts University Medical Center, Ms.

生态实验室由凯伦·韦克斯（KarenWeeks）创立，几十年来，她一直处于莱姆病研究和检测的前沿。她是关于蜱传疾病的广泛出版物的合著者，包括《新英格兰医学杂志》和《传染病杂志》。在监督马萨诸塞州公共卫生部病毒学部门的同时，与塔夫茨大学医学中心医学博士艾伦·斯特尔（AllenSteere）直接合作。

Weeks developed the Lyme Antibody Capture Immunoassay, which remains one of the most sensitive serology tests available for Lyme disease. In 1990, Ms. Weeks co-founded IMUGEN, Inc., the premier laboratory for the diagnosis of Lyme disease and many other tick-borne diseases, which was acquired by Oxford Immunotec in 2016.

Weeks开发了莱姆病抗体捕获免疫测定法，它仍然是莱姆病最敏感的血清学检测方法之一。1990年，Weeks女士共同创立了IMUGEN，Inc.，这是莱姆病和许多其他蜱传疾病诊断的首要实验室，2016年被牛津免疫技术公司收购。

'We look forward to entering into a strategic partnership with ECO Laboratory and its founder Karen Weeks, who has significant experience and expertise in the Lyme diagnostic market,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “Together, we plan to launch the T2Lyme Panel as a Laboratory Developed Test (LDT), for the detection or early Lyme disease, and build the premier Lyme testing laboratory in the United States.” .

T2 Biosystems董事长兼首席执行官约翰·斯佩泽尔（JohnSperzel）表示：“我们期待着与生态实验室及其创始人凯伦·韦克斯（KarenWeeks）建立战略合作伙伴关系，凯伦·韦克斯在莱姆诊断市场拥有丰富的经验和专业知识。”。“我们计划共同启动T2Lyme小组，作为实验室开发的检测（LDT），用于检测或早期莱姆病，并建立美国首屈一指的莱姆病检测实验室。”。